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Abstract
Background: Anxiety scales may help primary care physicians to detect specific anxiety disorders among the many
emotionally distressed patients presenting in primary care. The anxiety scale of the Four-Dimensional Symptom
Questionnaire (4DSQ) consists of an admixture of symptoms of specific anxiety disorders. The research questions
were: (1) Is the anxiety scale unidimensional or multidimensional? (2) To what extent does the anxiety scale detect
specific DSM-IV anxiety disorders? (3) Which cut-off points are suitable to rule out or to rule in (which) anxiety
disorders?
Methods: We analyzed 5 primary care datasets with standardized psychiatric diagnoses and 4DSQ scores.
Unidimensionality was assessed through confirmatory factor analysis (CFA). We examined mean scores and anxiety
score distributions per disorder. Receiver operating characteristic (ROC) analysis was used to determine optimal
cut-off points.
Results: Total n was 969. CFA supported unidimensionality. The anxiety scale performed slightly better in detecting
patients with panic disorder, agoraphobia, social phobia, obsessive compulsive disorder (OCD) and post traumatic
stress disorder (PTSD) than patients with generalized anxiety disorder (GAD) and specific phobia. ROC-analysis
suggested that ≥4 was the optimal cut-off point to rule out and ≥10 the cut-off point to rule in anxiety disorders.
Conclusions: The 4DSQ anxiety scale measures a common trait of pathological anxiety that is characteristic of
anxiety disorders, in particular panic disorder, agoraphobia, social phobia, OCD and PTSD. The anxiety score detects
the latter anxiety disorders to a slightly greater extent than GAD and specific phobia, without being able to
distinguish between the different anxiety disorder types. The cut-off points ≥4 and ≥10 can be used to separate
distressed patients in three groups with a relatively low, moderate and high probability of having one or more
anxiety disorders.
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Background
Several anxiety scales are being employed in research
and clinical practice for various reasons. Some scales,
often used in research, measure specific types of anxiety
(e.g., test anxiety, trait anxiety) or specific aspects of
individual anxiety disorders (e.g., worry, social anxiety,
specific fears) whereas other scales aim to measure a
common characteristic of most, if not all, anxiety states
or disorders (i.e., general anxiety) [1]. For use in primary
care practice general scales are more relevant because of
their promise to detect all or most types of anxiety dis-
order (i.e., panic disorder, agoraphobia, social phobia,
generalized anxiety disorder (GAD), posttraumatic stress
disorder (PTSD), obsessive compulsive disorder (OCD)
and specific phobia). Detection of anxiety disorders in
primary care is important because of their prevalence
and associated disability [2]. Research has shown that
general practitioners (GPs) recognize a mental health
problem in most of their patients with an anxiety dis-
order but they have difficulty recognizing a specific
anxiety disorder [3]. A solution to this problem might
be the use of a case finding instrument to distinguish
between patients with high risk of having an anxiety
disorder and patients with low risk. This tool must be
robust to prevalence variations as GPs will use it in
patient populations with various prevalence rates.
As relevant studies typically either lump different anx-
iety disorders together or focus on a limited number of
specific anxiety disorders, there is currently a lack of evi-
dence that available and popular anxiety scales are cap-
able of detecting all or most types of anxiety disorder in
primary care. Examples of popular anxiety scales are the
Hospital Anxiety and Depression Scale (HADS) [4], the
Beck Anxiety Inventory (BAI) [5], the anxiety scales of
the Depression Anxiety Stress Scale (DASS) [6] and the
Mood and Anxiety Symptom Questionnaire (MASQ)
[7,8], and the recently developed Generalized Anxiety
Disorder scale (GAD-7) [9,10]. The HADS is mainly used
in medical settings and appears to perform quite satisfac-
tory [11,12], but it may not detect all relevant types of anx-
iety disorder (e.g., social phobia) [13-15]. The BAI seems
to be biased towards panic disorder [16,17] and failed to
detect any anxiety disorder in some studies [18,19]. The
anxiety scale of the DASS also seems to favour panic
disorder [20]. The anxiety scale of the MASQ was
shown to be fairly good in detecting any anxiety dis-
order in a community sample [21], but in higher preva-
lence samples the scale discriminated poorly between
anxiety disorders and other or no disorders [22,23]. The
GAD-7 appears to be a good screener for GAD, panic
disorder, social anxiety disorder and PTSD in primary
care [9,10], but in higher prevalence samples the GAD-7
performed poorly in detecting GAD [24]. A few studies re-
ported the failure of anxiety scales to discriminate between
anxiety and depressive disorders [21,25,26], which may
suggest that some anxiety scales actually measure negative
affect or general distress [24].
The present study concerns the anxiety scale of the
Four-Dimensional Symptom Questionnaire (4DSQ). The
4DSQ is a self-rating questionnaire comprising four scales
measuring distress, depression, anxiety and somatization
[27]. The anxiety scale is composed of a collection of
symptoms that are more or less specific to the various
distinct anxiety disorders (see Table 1 for its items). This
raises questions about the dimensionality of the anxiety
scale. Is the anxiety scale unidimensional, measuring a sin-
gle trait of anxiety across different groups of patients (e.g.,
patients with different anxiety and depressive disorders or
no disorder), or is the anxiety scale multidimensional,
measuring different traits of anxiety in different patient
groups (e.g., panic anxiety in panic disorder patients, social
anxiety in social phobia patients and general anxiety in
GAD patients)? If the 4DSQ anxiety scale is multidimen-
sional, its scores could represent different anxiety prob-
lems depending on the specific anxiety disorder involved
and anxiety scores could not be compared across diagnos-
tic groups. For instance, an anxiety score of 15 could re-
flect a totally different problem in a panic disorder patient
than in a social phobia patient. From a practical point of
Table 1 Items of the 4DSQ anxiety scale, mean item
scores for the total sample (n = 969)a
Item # Item description Mean item
score
During the past week, −
21 - Did you suffer from a vague feeling of fear? 1.04
27 - Did you feel frightened? 0.91
18 - Did you suffer from sudden fright for no
reason?
0.73
44 - Were you afraid of becoming embarrassed
when with other people?
0.71
24 - Did you suffer from anxiety or panic attacks? 0.64
42 - Were you afraid of anything when there was
really no need for you to be afraid? (for
instance animals, heights, small rooms)
0.52
23 - Did you suffer from trembling when with other
people
0.50
50 - Did you have to repeat some actions a number
of times before you could do something else?
0.44
40 - Did you have any fear of going out of the
house alone?
0.42
45 - Did you ever feel as if you were being
threatened by unknown danger?
0.39
49 - Did you have to avoid certain places because
they frightened you?
0.36
43 - Were you afraid to travel on buses, streetcars/
trams, subways or trains?
0.33
aResponse options: no (code 0), sometimes (code 1), regularly (code 2), often
(code 2), very often or constantly (code 2).
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view the key question is whether the 4DSQ anxiety scale is
able to detect the various specific anxiety disorders equally
well (e.g., whether the scale will detect social phobia as
well as panic disorder). For the primary care professional
it is important to know whether the 4DSQ identifies all
anxiety disorders to the same extent or whether it tends to
detect some disorders preferentially and miss others.
It should be noted that the 4DSQ is not intended to
be used as a screening tool in unselected consecutive pa-
tients, but rather as an assessment and case finding instru-
ment in emotionally distressed patients. As noted above,
GPs usually recognize non-specific emotional problems in
patients with an anxiety disorder without recognizing that
these patients actually have an anxiety disorder that needs
specific treatment [3]. The 4DSQ, as a case finding instru-
ment, could assist GPs in separating patients with high
risk of having an anxiety disorder from patients with low
risk. The 4DSQ anxiety scale employs two cut-off points,
based on clinical experience [28], a lower cut-off point
with a relatively high sensitivity and a higher cut-off point
with a relatively high specificity. The idea is that the lower
cut-off point be used to identify a group of patients (below
the cut-off) with a relatively low probability of having an
anxiety disorder and that the higher cut-off point be used
to identify a group of patients (above the cut-off) with a
relatively high probability of having an anxiety disorder.
The latter group should be given priority in a subsequent
clinical diagnostic workup targeted at anxiety disorder.
The current cut-off points (≥8 and ≥13) are probably set
too high [29].
The present study evaluated the 4DSQ anxiety scale as
a case finding tool to identify anxiety disorder and aimed
to answer the following questions: (1) Is the 4DSQ anxiety
scale unidimensional or multidimensional and what is the
scale’s reliability? (2) To what extent does the 4DSQ anx-
iety scale detect each of the specific anxiety disorder types?
(3) Which cut-off points are suitable to rule out or to rule
in (which) anxiety disorders?
Methods
Study populations
The design was a cross-sectional secondary analysis of 5
convenience samples collected in different primary care
studies (total n = 969). Each of these samples consisted
of patients selected for having mental health problems,
defined in various ways. Each patient completed the
4DSQ and was subjected to a standardized psychiatric
interview administered by trained research assistants.
The range of disorders assessed differed across studies.
Dataset A contained the baseline data of general prac-
tice patients with emotional distress, who were assessed
for eligibility to take part in a randomized clinical trial to
investigate the effectiveness of a social work intervention
[30]. The diagnostic interview used was the Composite
International Diagnostic Interview (CIDI) [31], adminis-
tered face-to-face. The study was carried out in compli-
ance with the Helsinki Declaration and ethical approval
was granted by the Ethical Committee of the Netherlands
Institute of Mental Health and Addiction, Utrecht, the
Netherlands. Anonymized data were made available by
the Netherlands Institute for Health Services Research
(NIVEL), Utrecht, the Netherlands.
Dataset B consisted of the baseline data of general
practice patients with depressive symptoms, who were
assessed for eligibility to participate in a randomized
clinical trial to evaluate the effectiveness of antidepres-
sant pharmacotherapy [32]. The CIDI was administered
face-to-face. The study was carried out in compliance
with the Helsinki Declaration and ethical approval was
obtained from the Medical Ethical Committee of the VU
University Medical Center, Amsterdam, the Netherlands.
Anonymized data were made available by the EMGO
Institute for Health and Care Research, Amsterdam, the
Netherlands.
Dataset C comprised the baseline data of general prac-
tice patients with threshold and subthreshold mood and
anxiety disorders, who were included in a randomized
clinical trial to assess the effectiveness of a stepped care
program [33]. The CIDI was administered by telephone.
The study was carried out in compliance with the Helsinki
Declaration and ethical approval was obtained from the
Medical Ethical Committee of the VU University Medical
Center, Amsterdam, the Netherlands (registration number
2006/248). Anonymized data were made available by
the Department of Clinical Psychology, VU University,
Amsterdam, the Netherlands.
Dataset D consisted of the baseline data of general prac-
tice patients who were included in a randomized clinical
trial aimed to evaluate a stepped care program for mood,
anxiety and stress-related disorders [34]. The diagnostic
interview used was the Mini-International Neuropsychi-
atric Interview (MINI) [35], administered face-to-face.
The study was carried out in compliance with the Helsinki
Declaration and ethical approval was obtained from the
Medical Ethics Committee of the Twenteborg Hospital,
Almelo, the Netherlands. Anonymized data were made
available by Desiree B. Oosterbaan.
Dataset E was derived from a cross-sectional survey
among employees who had been unable to work for
more than two years due to mental health problems
and who applied for a work disability benefit according
to Dutch regulations [36]. The diagnostic interview
consisted of the CIDI, administered face-to-face. The
study was carried out in compliance with the Helsinki
Declaration and ethical approval was obtained from the
Medical Ethical Committee of the VU University Medical
Center, Amsterdam, the Netherlands. Anonymized data
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were made available by the Department of Psychiatry, VU
University Medical Center, Amsterdam, the Netherlands.
It should be noted that the selected patient samples
were all more or less representative of the so called “indi-
cated” population [37], the population in which the 4DSQ
anxiety scale is indicated to contribute to the separation of
patients with and without anxiety disorder.
Measures
Four-Dimensional Symptom Questionnaire (4DSQ)
The 4DSQ has been developed in primary care as a tool
to detect mental health problems, assess overall sever-
ity, and select patients with a high risk of having a de-
pressive or anxiety disorder. Importantly, the 4DSQ
dimensions were empirically derived through factor and
cluster analysis of a pool of 96 symptoms covering the
whole range of non-psychotic psychological and psy-
chosomatic symptoms, without prior assumptions about
the number and nature of the dimensions [38]. The
4DSQ comprises four scales measuring distress, depres-
sion, anxiety and somatization [27]. It takes on average
5–10 minutes to complete. The anxiety scale consists of
12 items measuring irrational fears, panic, avoidance,
and other features associated with anxiety disorders (see
Table 1). The scale’s reliability is generally good with
Cronbach’s alpha values generally well over 0.80. Response
categories are “no”, “sometimes”, “regularly”, “often”, “very
often or constantly”, which are scored as 0 for “no”, 1 for
“sometimes” and 2 for the other response categories. Item
scores are summated to obtain scale scores. The rationale
behind collapsing the highest response categories “regu-
larly”, “often”, “very often or constantly” into a single score
category is to avoid spurious correlations due to exagger-
ating response tendencies. This way of scoring ensures
that the scale score reflects primarily the number of symp-
toms rather than their subjective severity [39]. The 4DSQ
is freely available for non-commercial use as in health care
and research [40].
Standardized psychiatric interview
The studies employed two different diagnostic interviews,
the Composite International Diagnostic Interview (CIDI)
and the Mini-International Neuropsychiatric Interview
(MINI). The CIDI is a structured interview suitable to
be applied by trained lay interviewers [31]. It allows
standardized diagnoses of mental disorders according to
the definitions of the ICD-10 and DSM-IV (we used
DSM-IV diagnoses only). Reliability and validity are
generally good [41]. The MINI is also a structured inter-
view, but is it shorter than the CIDI [35]. The MINI has
good reliability and agreement with the CIDI [42]. As
both interviews are known to produce reliable and valid
DSM-IV diagnoses, we assumed that the CIDI and the
MINI interviews produced equivalent results. That is,
we assumed that, for instance, panic disorder diagnosed
in one study using the CIDI was essentially the same
disorder as panic disorder diagnosed in another study
using the MINI, although differences in prevalence and
severity across the studies might have existed. There
was no way to test our assumption of invariant diagno-
ses across studies, we simply had to rely on it. However,
it should be noted that major violation of this assump-
tion (e.g., when panic disorder according to the CIDI
was a different condition than panic disorder according
to the MINI) would have resulted in significantly de-
creased psychometric parameter estimates after pooling
the samples as the 4DSQ anxiety score would have been
compared to a hodgepodge of different conditions.
Analysis
To describe the study samples, we examined the compos-
ition of the samples regarding the prevalence of specific
disorders, the occurrence of multiple anxiety disorders and
comorbidity between anxiety and depressive disorders.
All analyses were performed in the five study samples
separately and, where possible, in the pooled sample of
five studies (total n = 969). Some anxiety disorders were
only assessed in two studies; in these cases the pooled
analyses were limited to the studies in which the specific
anxiety disorder was assessed.
To assess the dimensionality of the 4DSQ anxiety scale
we examined the fit indices of a one factor model using
confirmatory factor analysis (CFA) in the five studies sep-
arately. Fit indices examined were the χ2/df statistic, the
Root Mean Square Error of Approximation (RMSEA), the
Comparative Fit Index (CFI) and the Tucker-Lewis Index
(TLI). RMSEA values less than 0.08, χ2/df statistics less
than 3, and CFI and TLI values greater than 0.95 were
accepted as indicating adequate fit [43]. Strict factorial
invariance across all five studies was tested using a
multi-group CFA. The fit of the strict factorial invariance
was compared to a partial factorial invariance model (in
which the residual variances were allowed to differ be-
tween studies) using the χ2 test. CFA and multi-group
CFA analyses were performed in M-plus version 7 using
theta parameterisation [43].
As a measure of internal consistency reliability we deter-
mined the anxiety scale’s Cronbach’s alpha. We calculated
the anxiety scale’s standard error of measurement (SEM)
from the scale’s standard deviation (SD) and the alpha
coefficient, using the formula
SEM ¼ SD x 1–alphað Þ1=2:
The SEM, being the standard deviation of the meas-
urement error of the scale score, allows an estimation of
the confidence interval around individual scores. This
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information is useful for choosing and interpreting
practical cut-off points for the scale.
To assess the extent to which the 4DSQ anxiety scale
was able to detect the various specific anxiety disorders,
we explored the anxiety score distributions by drawing
boxplots for the individual anxiety disorders, for patients
with single and multiple anxiety disorders, and for patients
with depressive disorder(s) only, anxiety disorder(s) only,
and comorbid anxiety-depressive disorders. In addition,
we calculated mean anxiety scores and standard deviations
for the various diagnostic groups. Differences between
groups were tested using the non-parametric Kruskal-
Wallis test to account for the skewed score distribution
in some of the groups. Pair-wise post hoc tests were per-
formed using the software package “pgirmess” as imple-
mented in the statistical program R version 3.0.1 [44].
To determine optimal cut-off points for the 4DSQ
anxiety scale we performed receiver operating character-
istic (ROC) analyses with the anxiety score as the test
variable and anxiety disorders as the state variable, in
the separate studies and in the pooled samples. As it
turned out that the anxiety score seemed to be more
consistently associated with panic disorder, agoraphobia,
social phobia, OCD and PTSD than with GAD and spe-
cific phobia, we performed ROC analyses with the
former five disorders as state variable. Because only
panic disorder, agoraphobia and social phobia had been
assessed in all five studies, we first performed a ROC
analysis with these three disorders as outcome variable.
We determined the best ROC thresholds, being the
thresholds closest to the top-left corner of ROC graph
(i.e., sensitivity = 1, 1–specificity = 0). In addition, we
determined the highest thresholds with an arbitrarily
chosen sensitivity of ≥0.85, possibly suitable as the
lower cut-off point of the scale to rule out anxiety dis-
order when the test is negative, and the thresholds with
an arbitrarily chosen specificity of ≥0.85, possibly suit-
able as the higher cut-off point of the scale to rule in
anxiety disorder when the test is positive. We used
package “pROC” as implemented in R to perform the
ROC analyses and to estimate 95% confidence intervals
(95% CI) of the thresholds and operational parameters
using bootstrapping (2000 samples) [45]. Next, the ana-
lysis was repeated with panic disorder, agoraphobia, social
phobia, OCD or PTSD as outcome variable in the samples
in which the latter two disorders had been assessed.
A set of thresholds was chosen using all available infor-
mation. Finally, we calculated likelihood ratios to evaluate
the performance of these thresholds with respect to the
detection of panic disorder, agoraphobia and social phobia,
as well as to the detection of any anxiety disorder. The
likelihood ratio (LR) of a test result (e.g., a certain anxiety
score or a range of scores) is the ratio between the prob-
ability of this result in a population with the diagnosis of
interest (e.g., anxiety disorder) and the probability of this
result in a population without the diagnosis of interest
[46]. LRs are relatively independent of the prevalence of
the diagnosis of interest in the study population. Once
LRs are known, the probability of a diagnosis, given a cer-
tain test result and a certain prevalence, can be calculated
relatively easy because the LR is also the ratio between the
posterior odds of having a disorder and the prior odds of
having the disorder, with the latter simply being the preva-
lence divided by 1 minus the prevalence. The posterior
probability of having a disorder is the posterior odds di-
vided by 1 plus the posterior odds [46]. We have calcu-
lated LRs for the defined low, moderate and high anxiety
scores based on the pooled sample. Subsequently, we used
these LRs to calculate the predictive value of low, moder-
ate and high anxiety scores with respect to ruling in or rul-
ing out panic disorder, agoraphobia and social phobia, and
any anxiety disorder respectively, in two hypothetical sam-
ples, one similar to our pooled sample, the other with half
the prevalence of anxiety disorder. LRs and their confi-
dence intervals were calculated using the website for stat-
istical computation VassarStats (http://vassarstats.net/).
The analyses, other than the CFAs, the ROC-analyses
and the post hoc analyses after the Kruskal-Wallis tests,
were performed using SPSS 20.0.
Results
Prevalence and comorbidity
Details of the study samples are presented in Table 2. The
diagnostic composition of the samples varied to some
extent. Studies that focused on the whole spectrum of
depressive and anxiety disorders (studies C, D and E)
selected relatively more patients with anxiety disorders.
Study B that focused on patients with depressive com-
plaints included relatively more patients with depressive
disorders and fewer patients with anxiety disorder, except
for GAD. We refrained from formal statistical testing of
these between-study differences because generalization of
these differences would serve no purpose. It suffices to
note that there was some heterogeneity between the study
samples, which likely resulted from the different settings
and purposes for which the samples had been collected.
Table 3 shows the prevalence of multiple anxiety disor-
ders and the co-occurrence of anxiety and depressive
disorders (anxiety-depression comorbidity). For instance,
of all patients across the study samples diagnosed with
panic disorder (n = 176) 86% had one or more other anx-
iety disorders too, and 59% of the panic disorder patients
had a comorbid depressive disorder (i.e., major depressive
disorder or dysthymia). For each of the specific anxiety
disorders, the occurrence of multiple anxiety disorders
(56-88%) and anxiety-depression comorbidity (55-74%)
was more the rule than an exception. Of all patients with
one or more anxiety disorders (n = 477), 228 (48%) had a
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single anxiety disorder, which was most frequently (in
99 cases) GAD. It should be noted that the already high
prevalence of multiple anxiety disorders was probably
underestimated to some extent because specific phobia,
OCD and PTSD had not been assessed in three studies
(see Table 2).
Unidimensionality and reliability
The results of the CFAs are displayed in Table 4. For all
studies separately the one factor model showed adequate
fit. Moreover, for the studies combined, the strict factor-
ial invariance model showed adequate fit on all indices.
Fit of the strict factorial invariance model was not worse
Table 2 Description of the datasets
Study A B C D E
Numbersa 295 170 118 156 230
Gender (% female) 60.3 72.4 64.4 61.5 67.8
Age [mean (SD)] 39.5 (9.2) 44.9 (15.9) 49.5 (11.2) 38.1 (12.1) 43.5 (7.5)
4DSQ scores [mean (SD)]
- Distress (range 0–32) 22.9 (7.2) 21.0 (7.5) 19.4 (7.1) 19.8 (9.2) 20.7 (9.0)
- Depression (range 0–12) 4.0 (3.4) 4.3 (3.8) 3.7 (3.1) 4.4 (4.0) 4.9 (4.4)
- Anxiety (range 0–24) 5.9 (5.4) 5.9 (5.8) 7.0 (5.2) 6.6 (6.3) 9.4 (7.3)
- Somatization (0–32) 14.2 (6.9) 12.7 (7.2) 14.2 (6.9) 12.0 (8.0) 14.7 (7.7)
DSM-IV diagnoses (%)
- Panic disorderb 7.8 8.8 26.3 26.3 28.7
- Agoraphobiac 7.1 12.4 32.2 21.8 27.0
- Social phobia 10.8 7.1 22.9 21.2 23.5
- GADd 20.7 32.9 18.6 16.7 26.1
- Specific phobia N/A 17.1 N/A 8.3 N/A
- OCDe N/A N/A N/A 5.1 17.0
- PTSDf N/A N/A N/A 3.8 20.0
- Major depressive disorder 49.5 67.1 42.4 50.6 40.0
- Dysthymia 2.4 18.2 12.7 3.8 28.7
aNumbers of patients refer to those who completed the 4DSQ and a diagnostic interview.
bPanic disorder without agoraphobia plus panic disorder with agoraphobia.
cAgoraphobia without history of panic disorder plus panic disorder with agoraphobia.
dGeneralized anxiety disorder.
eObsessive compulsive disorder.
fPost traumatic stress disorder.
N/A: not assessed.
Table 3 Occurrence of multiple anxiety disorders and anxiety-depression comorbidity, over the study samples pooled
and the range across the separate study samples
Disorder N Multiple anxiety disorders (%)a Anxiety-depression comorbidity (%)a
pooled range pooled range
Panic disorderb 176 86 70-96 59 39-80
Agoraphobiac 176 88 71-95 56 37-76
Social phobia 158 71 58-80 63 41-83
GADd 225 56 30-80 66 50-79
Specific phobia 42 59 46-66 74 46-86
OCDe 47 85 82-100 55 54-63
PTSDf 52 73 72-83 63 61-83
aPercentages of patients with specific anxiety disorders who also had one or more other anxiety disorders or comorbid depressive disorder.
bPanic disorder without agoraphobia plus panic disorder with agoraphobia.
cAgoraphobia without history of panic disorder plus panic disorder with agoraphobia.
dGeneralized anxiety disorder.
eObsessive compulsive disorder.
fPost traumatic stress disorder.
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than that of the partial factorial invariance model (χ2 =
57.6, df = 48, p = 0.162).
Cronbach’s alpha varied between 0.85 (study C) and
0.92 (study E) and was 0.90 in the pooled sample. The
anxiety scale’s standard deviation varied between 5.2
(study C) and 7.3 (study E) and was 6.2 in the pooled
sample. The SEM varied between 1.9 (studies A and B)
and 2.0 (studies C-E) and was 2.0 in the pooled sample.
This value of SEM means that, due to measurement
error, the 96% confidence interval of a given score X was
X ± 4 points and that the 84% confidence interval of a
given score X was X ± 3 points.
Anxiety score distributions
The boxplots depicting the disorder-specific anxiety
score distributions (Figure 1) suggest a difference in
overall level of anxiety, as measured by the 4DSQ anx-
iety scale, between GAD and specific phobia on the one
hand and panic disorder, agoraphobia, social phobia,
OCD and PTSD on the other hand. It appeared that, on
average, panic disorder, agoraphobia, social phobia, OCD
and PTSD were characterized by slightly higher anxiety
scores than GAD and specific phobia.
Figure 2 demonstrates the differences in anxiety score
associated with the number of anxiety disorders per
patient. The median anxiety score for patients with sin-
gle anxiety disorders was 7 whereas the median score for
patients with three or more anxiety disorders was 16.
Clearly, the anxiety score was an indicator of the num-
ber of anxiety disorders per patient. Of the patients with
three or more anxiety disorders over 50% scored very
high (i.e., ≥16) and less than 10% scored low (i.e., <4). In
contrast, no more than 10% of patients with single anx-
iety disorders scored very high (i.e., ≥16) and 29% scored
low (i.e., <4). As noted above, GAD was the most fre-
quent diagnosis in the single anxiety disorder group
(43%). Also relevant for the ability of the anxiety score
to detect anxiety disorders was the finding that only 11%
of patients without a diagnosed anxiety disorder scored
≥10. An anxiety score ≥10 indicated a relatively high
probability of having one or more anxiety disorders.
Note that Figure 2 does not account for comorbidity
with depressive disorder.
Anxiety-depression comorbidity was also strongly re-
lated with the anxiety score distribution (Figure 3). Of
the patients with non-comorbid anxiety disorders 27%
scored low (i.e., <4) on the anxiety scale and 54% of
them had a single anxiety disorder. The presence of
depressive disorder was also associated with an increase
in the anxiety score, although a smaller increase than
the increase associated with the presence of anxiety
disorder.
Mean anxiety scores per disorder are displayed in
Table 5. The highest mean scores occurred in patients
with panic disorder, agoraphobia, OCD, PTSD and so-
cial phobia. The mean anxiety score appeared to be
strongly associated with the number of anxiety disor-
ders per patient (Kruskal-Wallis test p <0.001). To ac-
count for multiple pair-wise comparisons between four
groups (6 comparisons) we adopted a critical p-value of
0.0083 (0.05/6) for the post hoc tests. All between group
tests were significant (p <0.0083). By the same token, the
comorbidity groups were significantly different (Kruskal-
Wallis test p < 0.001). Post hoc tests (with the same adjust-
ment for multiple testing) revealed that all between-group
differences were significant (p <0.0083).
In conclusion, the anxiety scale appeared to detect
multiple anxiety disorders better than single anxiety
disorders, comorbid anxiety-depressive disorders better
than non-comorbid anxiety disorders, and panic dis-
order, agoraphobia, social phobia, OCD and PTSD better
than GAD and specific phobia.
ROC analysis
ROC analysis with panic disorder, agoraphobia and so-
cial phobia as the outcome variable revealed area under
the curve (AUC) values in the separate studies between
0.737 and 0.857 (Table 6). In the pooled sample the
AUC was 0.793 (95% CI 0.763 – 0.822) indicating that
the overall diagnostic accuracy was fair [47]. The best
ROC threshold nearest to the top-left corner of the
ROC-graph (i.e., sensitivity =1 and 1–specificity = 0)
Table 4 Fit indices of single factor model for studies separately and for the strict and partial factorial invariance model
for all studies together
Study χ2 df p χ2/df RMSEA CFI TLI
Study A 156.6 54 <0.0001 2.9 0.080 0.966 0.958
Study B 115.6 54 <0.0001 2.1 0.082 0.966 0.958
Study C 83.0 54 0.0068 1.5 0.067 0.971 0.964
Study D 88.4 54 0.0022 1.6 0.064 0.986 0.983
Study E 87.6 54 0.0026 1.6 0.052 0.993 0.991
Studies A-E strict factorial invariance model 639.3 406 <0.0001 1.6 0.054 0.983 0.986
Studies A-E partial factorial invariance model 645.7 358 <0.0001 1.8 0.064 0.979 0.981
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varied between 4.5 and 8.5. Note that ROC-analysis
defines thresholds in between observed scores, hence a
threshold of 4.5 is equivalent to a cut-off point ≥5. The
best ROC threshold in the pooled sample was 6.5 (95%
CI 5.5–7.5). The lower threshold with sensitivity ≥0.85
varied between 1.5 and 5.5 across the studies, and was
3.5 in the pooled sample. The higher threshold with spe-
cificity ≥0.85 varied between 8.5 and 15.5, and was 10.5
in the pooled sample. The thresholds demonstrated sub-
stantial variability across the studies. Note also that the
confidence intervals of the thresholds in the individual
studies were rather wide, depending on the sample size.
In the pooled sample the confidence interval of the
threshold was reduced to ±1. Note further that the lower
threshold was associated with a high negative predictive
value (npv) of 0.89 (0.86–0.92) in the pooled sample,
and that the higher threshold was associated with a rela-
tively high positive predictive value (ppv) of 0.65 (0.59–
0.70) for the detection of panic disorder, agoraphobia or
social phobia. The repeated analysis with panic disorder,
agoraphobia, social phobia, OCD or PTSD as the out-
come variable showed an AUC in the pooled sample of
studies D and E of 0.807 (95% CI 0.761–0.848). The best
ROC threshold was 6.5 (4.5–8.5) with sensitivity of 0.73
(0.67–0.78), specificity of 0.75 (0.69–0.81), ppv of 0.77
(0.73–0.82) and npv of 0.70 (0.65–0.75). The lower
Figure 1 Disorder-specific 4DSQ anxiety score distributions. Separate boxplots for specific phobia (SPEC), generalized anxiety disorder (GAD),
social phobia (SOC), panic disorder (PAN), agoraphobia (AGO), obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD). The
boxes of the boxplots represent the median scores and the interquartile ranges. The whiskers of the plots reach to the extreme scores.
Figure 2 4DSQ anxiety score distributions by number of anxiety disorders per patient. The boxes of the boxplots represent the median
scores and the interquartile ranges (IQR). The whiskers of the plots reach to the extreme scores, with a maximum distance to the box of 1.5 IQR.
Outliers are represented by dots (distance to the box of 1.5-3 IQR) or asterisks (distance to the box of >3 IQR).
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Figure 3 4DSQ anxiety score distributions by comorbidity groups. The boxes of the boxplots represent the median scores and the
interquartile ranges (IQR). The whiskers of the plots reach to the extreme scores, with a maximum distance to the box of 1.5 IQR. Outliers are
represented by dots (distance to the box of 1.5-3 IQR) or asterisks (distance to the box of >3 IQR).
Table 5 Mean anxiety scores per anxiety disorder, per number of anxiety disorders and per comorbidity group, over
the study samples pooled and the range across the separate study samples
Pooled Range
N Mean (SD) Mean (SD)
Anxiety disorder
- Panic disordera 176 12.6 (6.2) 9.8 – 14.8 (4.2 – 7.5)
- Agoraphobiab 176 12.9 (6.6) 9.0 – 15.5 (5.4 – 6.6)
- Social phobia 158 11.9 (6.8) 9.3 – 15.1 (5.4 – 7.4)
- GADc 225 9.9 (6.5) 8.0 – 13.7 (5.1 – 6.9)
- Specific phobia 42 9.5 (6.4) 7.6 – 10.4 (6.4 – 6.4)
- OCDd 47 12.8 (7.0) 7.8 – 13.9 (4.4 – 7.0)
- PTSDe 52 12.9 (6.7) 10.7 – 13.2 (5.0 – 6.9)
Number of anxiety disorders
- 0 492 4,1 (4,4) 3.1 – 4.7 (3.9 – 5.3)
- 1 228 7,4 (5,3) 6.0 – 8.5 (4.3 – 6.3)
- 2 148 10,6 (5,8) 8.6 – 12.3 (5.0 – 6.3)
- ≥ 3 101 15,1 (6,0) 12.4 – 17.3 (5.0 – 6.5)
Comorbidity groups
- No anxiety or depressive disorder 263 3.2 (4.0) 1.8 – 5.4 (2.7 – 4.9)
- Depressive disorder(s)f only 229 5.0 (4.7) 4.1 – 9.2 (3.7 – 5.9)
- Anxiety disorder(s) only 198 8.3 (5.9) 6.5 – 9.9 (5.2 – 6.5)
- Comorbid anxiety and depressive disorders 279 11.3 (6.5) 8.6 – 14.2 (4.7 – 6.7)
aPanic disorder without agoraphobia plus panic disorder with agoraphobia.
bAgoraphobia without history of panic disorder plus panic disorder with agoraphobia.
cGeneralized anxiety disorder.
dObsessive compulsive disorder.
ePost traumatic stress disorder.
fMajor depressive disorder and/or dysthymia.
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threshold was 2.5 (1.5–3.5) with sensitivity of 0.88
(0.84–0.93), specificity of 0.47 (0.39–0.55), ppv of 0.66
(0.63–0.70) and npv of 0.78 (0.71–0.85). The higher
threshold was 9.5 (7.5–11.5) with sensitivity of 0.60
(0.53–0.66), specificity of 0.86 (0.81–0.91), ppv of 0.83
(0.78–0.89) and npv of 0.65 (0.61–0.69). Note the in-
crease of the ppv (from 0.65 to 0.83) of the higher
threshold by the inclusion of OCD and PTSD in the out-
come, despite the use of a 1 point lower threshold.
Likelihood ratios and predicted probabilities
Based on the ROC-analyses, we decided to choose ≥4
and ≥10 as the revised lower and higher cut-off points
for the 4DSQ anxiety scale. The lower cut-off point (≥4)
identified 85-90% of all patients with panic disorder,
agoraphobia, social phobia, OCD or PTSD and 80% of
all patients with GAD or specific phobia. The higher
cut-off point (≥10) identified two thirds of all patients
with panic disorder, agoraphobia, social phobia, OCD or
PTSD and 50% of all patients with GAD or specific pho-
bia. Anxiety disorder patients who scored low (<4) on
the anxiety scale, consisted mainly of patients with single
anxiety disorders (73%) and patients with non-comorbid
disorders (60%) whereas 50% of them had GAD. The
percentage of patients with anxiety scores 4–9 varied
between 25% and 42% in the separate study samples,
and was 31% in the pooled sample.
The LRs associated with low, moderate and high anx-
iety scores are presented in Table 7. The prevalence of
panic disorder, agoraphobia and social phobia in the
pooled sample was 317/969 = 32.7%. The likelihood of
scoring 0–3 among patients with panic disorder, agora-
phobia and social phobia was 42/317 = 0.132, whereas
this likelihood among patients without panic disorder,
agoraphobia and social phobia was 332/652 = 0.509. The
ratio of these likelihoods was 0.132/0.509 = 0.259. Table 8
presents the predicted probabilities of having panic
disorder, agoraphobia or social phobia, or any anxiety
disorder respectively, based on the LR and the 4DSQ
anxiety score. The probabilities were calculated using
the following equations:
prior odds ¼ prevalence= 1–prevalenceð Þ
posterior odds ¼ prior odds  LR
probability ¼ posterior odds= 1þ posterior oddsð Þ:
As expected, low anxiety scores (0–3) predicted rela-
tively low probabilities of having an anxiety disorder and
high anxiety scores (10–24) predicted relatively high
Table 6 Results of the ROC-analysis with panic disorder/agoraphobia/social phobia as outcome variable
Study A B C D E Pooled A-E
Total numbers 295 170 118 156 230 969
Prevalencea 19.0% 16.5% 50.0% 48.7% 42.6% 32.7%
AUCb (95% CI) .851 (.803; .896) .857 (.774; .927) .737 (.643; .820) .787 (.714; .855) .775 (.714; .834) .793 (.763; .822)
Best thresholdc (95% CI) 7.5 (5.5; 8.5) 8.5 (4.5; 12.5) 5.5 (4.5; 8.5) 4.5 (3.5; 6.5) 7.5 (6.5; 11.5) 6.5 (5.5; 7.5)
- Sensitivity (95% CI) .79 (.68; .89) .71 (.54; .86) .71 (.59; .83) .75 (.64; .84) .79 (.70; .86) .74 (.69; .79)
- Specificity (95% CI) .77 (.72; .83) .84 (.77; .89) .63 (.51; .75) .73 (.63; .83) .67 (.59; .75) .71 (.67; .75)
- ppvd (95% CI) .45 (.39; .52) .47 (.36; .59) .63 (.58; .75) .72 (.65; .80) .64 (.58; .70) .55 (.52; .59)
- npve (95% CI) .94 (.91; .97) .94 (.90; .97) .69 (.60; .78) .75 (.68; .83) .81 (.75; .87) .85 (.82; .87)
Lower thresholdf (95% CI) 5.5 (3.5; 7.5) 4.5 (1.5; 8.5) 2.5 (1.5; 4.5) 1.5 (0.5; 3.5) 3.5 (2.5; 7.5) 3.5 (2.5; 4.5)
- Sensitivity (95% CI) .86 (.75; .95) .89 (.79; 1.00) .88 (.80; .97) .91 (.84; .96) .87 (.80; .93) .87 (.83; .90)
- Specificity (95% CI) .68 (.62; .74) .62 (.54; .70) .37 (.25; .49) .43 (.31; .54) .42 (.33; .50) .51 (.47; .55)
- ppvd (95% CI) .39 (.34; .44) .32 (.27; .37) .58 (.53; .64) .60 (.55; .65) .52 (.49; .57) .46 (.44; .49)
- npve (95% CI) .95 (.92; .98) .97 (.93; 1.00) .76 (.61; .91) .83 (.72; .93) .81 (.73; .89) .89 (.86; .92)
Higher thresholdg (95% CI) 10.5 (8.5; 11.5) 9.5 (7.5; 11.5) 9.5 (7.5; 12.5) 8.5 (6.5; 12.5) 15.5 (11.5; 17.5) 10.5 (9.5; 11.5)
- Sensitivity (95% CI) .57 (.45; .70) .64 (.46; .82) .42 (.31; .56) .50 (.38; .61) .43 (.32; .52) .52 (.46; .57)
- Specificity (95% CI) .89 (.85; .93) .86 (.80; .92) .86 (.78; .95) .89 (.81; .95) .87 (.81; .92) .86 (.83; .89)
- ppvd (95% CI) .54 (.45; .65) .47 (.36; .61) .76 (.63; .89) .81 (.71; .91) .71 (.61; .82) .65 (.59; .70)
- npve (95% CI) .90 (.87; .93) .92 (.89; .96) .60 (.54; .66) .65 (.60; .71) .67 (.63; .71) .79 (.77; .81)
aPrevalence of panic disorder/agoraphobia/social phobia.
bArea under the ROC curve.
cThreshold closest to top-left corner of ROC graph (i.e., sensitivity = 1, (1-specificity) = 0).
dPositive predictive value.
eNegative predictive value.
fLower threshold = highest threshold with sensitivity ≥0.85.
gHigher threshold = lowest threshold with specificity ≥0.85.
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probabilities, depending on the prevalence of anxiety
disorder. Note that low anxiety scores are relatively good
in ruling out panic disorder, agoraphobia and social pho-
bia but perform relatively poorly in ruling out any anx-
iety disorder, especially in high prevalence samples. The
obvious reason is that, as we have seen before, about
one fifth of patients with GAD or specific phobia have low
anxiety scores. On the other hand, high anxiety scores do
a relatively good job in ruling in (any) anxiety disorder.
The LRs associated with moderate anxiety scores (4–9)
were close to 1 and, consequently, the posterior probabil-
ity was close to the prevalence of anxiety disorder. Moder-
ate anxiety scores are little informative.
Discussion
Our results suggest that, in primary care patients, the
4DSQ anxiety scale measures a unidimensional construct.
In other words, the scale seems to measure a common
trait of anxiety symptoms that is present to a lesser or
greater extent in various patient groups. This common
trait of pathological anxiety appears to be present to a
greater extent in patients with panic disorder, agoraphobia,
social phobia, OCD and PTSD, and to a slightly lesser ex-
tent in patients with GAD and specific phobia. It is absent,
or present to a relatively small extent, in patients with
non-comorbid depressive disorders and in emotionally
distressed patients without any anxiety or depressive dis-
order. Notwithstanding the fact that the 4DSQ anxiety
scale consists of an admixture of vague anxiety symptoms
(e.g., vague feeling of fear, feeling frightened) and symp-
toms that are more or less specific to distinct anxiety
disorder types (e.g., anxiety or panic attacks, irrational
specific fears, fear of public embarrassment, repeating
actions, avoiding places, fear of public transport) the
anxiety scale symptoms appear to work together to
measure a common dimension of pathological anxiety.
Although the specific anxiety disorders are conceptual-
ized as separate disorders in DSM-IV, in our samples,
the specific anxiety disorders relatively rarely occurred
stand-alone as single disorders. Multiple anxiety disor-
ders were the rule, rather than an exception. This might,
in part, explain why we found the anxiety scale to be
unidimensional. Additional research is needed to clarify
the dimensions of anxiety symptoms and disorders.
The kind of anxiety that is measured by the 4DSQ
anxiety scale was present in most patients with anxiety
disorders. This finding compares favourably to existing
anxiety scales. However, this anxiety was present to a
slightly greater extent in patients with panic disorder,
agoraphobia, social phobia, OCD or PTSD than in pa-
tients with GAD or specific phobia, and undeniably it
was present to a greater extent in patients with multiple
Table 7 Likelihoods and likelihood ratios associated with low (0–3), moderate (4–9) and high (10–24) 4DSQ anxiety
scores with respect to panic disorder, agoraphobia and social phobia, and to any anxiety disorder respectively
Panic disorder, agoraphobia and social phobia Any anxiety disorder
Anxiety score Total N Disorder No disorder Disorder No disorder
N LHa N LHa LR (95% CI)b N LHa N LHa LR (95% CI)b
0-3 374 42 0.13 332 0.51 0.26 (0.19; 0.35) 90 0.19 284 0.58 0.33 (0.27; 0.40)
4-9 301 92 0.29 209 0.32 0.91 (0.74; 1.11) 145 0.30 156 0.32 0.96 (0.79; 1.16)
10-24 294 183 0.58 111 0.17 3.39 (2.79; 4.12) 242 0.51 52 0.11 4.80 (3.66; 6.30)
Total 969 317 1 652 1 477 1 492 1
aLH = likelihood of anxiety score within the Anxiety disorder group and No anxiety disorder group respectively.
bLR = likelihood ratio.
Table 8 Predicted probabilities for panic disorder, agoraphobia and social phobia, and for any anxiety disorder
respectively based on the prevalence and likelihood ratios associated with low (0–3), moderate (4–9) and high (10–24)
4DSQ anxiety scores
Panic disorder, agoraphobia and social phobia Any anxiety disorder
Anxiety score LR (95% CI)c Prevalence = 0.33a
(prior odds = 0.49)
Prevalence = 0.16b
(prior odds = 0.19)
LR (95% CI)c Prevalence = 0.49a
(prior odds = 0.96)
Prevalence = 0.25b
(prior odds = 0.33)
Prob. (95% CI)d Prob. (95% CI)d Prob. (95% CI)d Prob. (95% CI)d
0-3 0.26 (0.19; 0.35) 0.12 (0.08; 0.15) 0.05 (0.04; 0.07) 0.33 (0.27; 0.40) 0.24 (0.21; 0.28) 0.10 (0.08; 0.12)
4-9 0.91 (0.74; 1.11) 0.31 (0.26; 0.35) 0.15 (0.12; 0.17) 0.96 (0.79; 1.16) 0.48 (0.43; 0.53) 0.24 (0.21; 0.28)
10-24 3.39 (2.79; 4.12) 0.62 (0.58; 0.67) 0.39 (0.35; 0.44) 4.80 (3.66; 6.30) 0.82 (0.78; 0.86) 0.61 (0.55; 0.68)
aPrevalence based on the pooled sample in this study.
bHalf the prevalence in the pooled sample in this study.
cLR = likelihood ratio.
dProb. = predicted posterior probability of disorder given the prevalence and anxiety score.
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anxiety disorders than in patients with single anxiety dis-
orders, and in comorbid anxiety-depressive disorders
than in non-comorbid anxiety disorders. Still, the major-
ity of patients with GAD or specific phobia (79%), single
anxiety disorders (71%) and non-comorbid anxiety disor-
ders (73%) scored at or above the lowest cut-off point
(≥4). Nevertheless, 20-30% of these disorders scored low
(<4). In contrast, 85-90% of patients with panic disorder,
agoraphobia, social phobia, OCD or PTSD, multiple anx-
iety disorders or comorbid anxiety-depressive disorders
scored ≥4. When it comes to detecting anxiety disorders
in primary care patients, the 4DSQ performs better with
respect to panic disorder, agoraphobia, social phobia,
OCD or PTSD, multiple anxiety disorders and comorbid
anxiety-depressive disorders.
A sufficiently strong association between the 4DSQ
anxiety score and the presence of anxiety disorder con-
stitutes a prerequisite for the anxiety score to be useful
as a tool to detect anxiety disorder. This association
depends, first of all, on the concordance of whatever the
anxiety scale is measuring and what characterizes anx-
iety disorder (a matter of validity). In the hypothetical
situation that there is 100% concordance, all patients
scoring above a certain threshold on the anxiety scale
would have an anxiety disorder and all patients scoring
below that threshold would not. In practice, of course,
the concordance is rarely 100%. In the present study
there was evidence that very high anxiety scores not
always implied a diagnosable anxiety disorder, and, con-
versely, that very low anxiety scores did not always imply
the absence of anxiety disorder diagnosis. A possible rea-
son for high anxiety scores in the absence of an anxiety
disorder diagnosis might be that the patient did not fulfil
all necessary criteria for a diagnosis (regarding e.g., dur-
ation, distress or disability). A possible reason for low
anxiety scores in the presence of anxiety disorder might
be that in some anxiety disorder cases manifest anxiety
(as measured by the 4DSQ) was not a prominent feature
of the disorder or was not necessarily present all the
time. This happened relatively more often in cases diag-
nosed as GAD or specific phobia.
The observed association between the anxiety score
and the diagnosis of anxiety disorder is also determined
by the amount of measurement error, both in the anxiety
score and in the assessment of the anxiety disorder diag-
nosis. Measurement error in the anxiety disorder diagnosis
translates into misclassification and reduced reliability of
the diagnosis. In our studies diagnostic reliability was not
assessed, but typically the interrater agreement (Cohen’s
kappa) of anxiety disorder diagnoses varies between
0.60 and 0.80 [41]. A kappa of 0.70 means 70% agree-
ment after correction for chance agreement. Consid-
ering that there is a continuity between normality
and anxiety disorder, it should be realized that the
risk of misclassification is greatest near the threshold
of disorder.
The mean reliability of the anxiety score across the
study samples was 0.90, yielding a SEM of 2 points, sug-
gesting that the 84% confidence interval of a given ob-
served anxiety score X was X ± 3. In other words, when
the observed anxiety score was X, we could be at least
92% confident that the true score was not > (X + 3) and
we could also be at least 92% confident that the true
score was not < (X–3).
When performing ROC analyses, we observed wide con-
fidence intervals and significant variability of the thresh-
olds across the studies. This variability must be attributed
to differences in prevalence and severity spectrum of the
samples, and also to distributional irregularities produced
by chance in relatively small samples. Combining the sam-
ples by pooling was a logical action in order to obtain
more stable estimates. This way we obtained 6.5 as the
best single threshold to detect panic disorder, agoraphobia,
social phobia, OCD and PTSD. Yet, using this single
threshold would misclassify over a quarter of patients in
either group. Therefore, we chose two thresholds, one
(3.5) with a relatively high sensitivity to single out patients
with a relatively low probability of having panic disorder,
agoraphobia, social phobia, OCD or PTSD and one
threshold (9.5) with a relatively high specificity to single
out patients with a relatively high probability of having
panic disorder, agoraphobia, social phobia, OCD or PTSD.
Note that both thresholds are 1.5 SEM away from the
threshold (6.5) of panic disorder, agoraphobia, social pho-
bia, OCD and PTSD. This implies that we can be more
than 92% confident that patients with anxiety scores 0–3
do not have a true anxiety score above the threshold of
panic disorder, agoraphobia, social phobia, OCD and
PTSD. Conversely, we can be more than 92% confident
that patients with anxiety scores 10–24 do not have a true
anxiety score below the threshold of panic disorder, agora-
phobia, social phobia, OCD and PTSD. The uncertainty
about whether or not a patient has passed the threshold of
panic disorder, agoraphobia, social phobia, OCD and
PTSD has now been restricted to one third (25-42%) of all
patients, who score 4–9 on the anxiety scale.
The primary care professional can use the two cut-off
points of the 4DSQ anxiety scale to separate patients
with mental health problems into three groups: (1) a
group with high anxiety scores (10–24), (2) a group with
moderate scores (4–9), and (3) a group with low scores
(0–3). Patients with high anxiety scores have a relatively
high probability of having one or more anxiety disorders.
Importantly, a high anxiety score does not represent a
clinical diagnosis in itself. In addition, as noted earlier,
the 4DSQ anxiety score does not indicate which specific
anxiety disorder(s) is (are) present. A clinical diagnosis
should be made in the short term using clinical judgment
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and available clinical guidelines [48,49]. Given the likeli-
hood ratio, the chance of diagnosing one or more anxiety
disorders is relatively high. Moreover, patients with high
anxiety scores tend to have relatively clear-cut disorders as
most borderline anxiety disorders are classified into the
moderate group. On the other hand, patients with low
anxiety scores have a low probability of anxiety disorder
and when they do have an anxiety disorder, it will often be
GAD or specific phobia, or a borderline anxiety disorder.
These patients do not need a diagnostic interview targeted
at anxiety disorder for the time being. Probably, in this
low anxiety scores group, other problems (e.g., depression,
stressful life situations) are more important to address. In
the middle group with moderate anxiety scores (which
constituted one third of our pooled sample), the possibility
of anxiety disorder has not been ruled out as the probabil-
ity is about the same as the prevalence. Anxiety disorder
cases in this group are relatively often just beyond the
diagnostic threshold and other problems (e.g., depression,
stress) might be in more need of treatment. We argue that
a diagnostic workup targeted at anxiety disorder can be
postponed for a few weeks while monitoring the effect
of non-specific interventions (e.g., reassurance, encour-
agement, advice) and the passage of time. When after
3–4 weeks symptoms decline, further diagnostic workup
targeted at anxiety disorder does not seem to be necessary,
but when symptoms do not abate a diagnostic interview is
warranted after all. In our experience, this way GPs can
efficiently target their diagnostic efforts to patients with a
relatively high risk of having an anxiety disorder while
keeping patients with moderate risk under surveillance.
We acknowledge that there is currently no firm evidence
to support this strategy, but it is our impression that it
works fine in the primary care setting. More research is
needed in this area.
The main limitation of the present study relates to the
representativeness of the datasets included. Each of the
datasets had been collected for other purposes than to
evaluate the measurement properties of the 4DSQ. We
would have preferred a large representative sample of
primary care patients with mental health problems, each
extensively assessed using a standardized psychiatric
interview. However, this is costly and logistically challen-
ging. Therefore, we employed convenience datasets col-
lected in other studies. We assumed that the psychiatric
diagnoses were principally invariant across the study
samples as the samples could all be considered draws
from the same large pool of primary care patients with
mental health problems. Due to sampling differences, a
fair degree of heterogeneity across the studies was evi-
dent, but this probably represented a strength of our
study instead of a weakness. Furthermore, as the 4DSQ
anxiety scale demonstrated high reliability and identical
measurement properties across the studies, we assumed
that the operating characteristics of the scale (i.e., sensi-
tivity and specificity) were principally the same across
the studies, only varying due to sampling. Therefore, we
assumed that pooling (i.e., effectively conducting a patient
level meta-analysis) was the best way to obtain valid esti-
mates for the operating characteristics of the anxiety scale.
A second limitation concerns the fact that some studies
did not assess the whole range of anxiety disorders. Not-
ably, specific phobia, OCD and PTSD were not included
in three studies. We estimate that if these diagnoses would
have been established with a prevalence of 10-15%, assum-
ing that at least two thirds of these disorders would co-
occur with another (already known) anxiety disorder, the
total increase in anxiety disorder patients across the stud-
ies would amount to 5-10%. This would have lead to a
small decrease in the anxiety scores of patients without
anxiety disorder. We assume that this would not have
changed the results in any substantial way. However, repli-
cation in new samples would be desirable.
A third limitation constitutes the lack of information
about interrater reliability of the diagnostic interviews.
We relied on the reported reliability of these standardized
interviews when performed by carefully trained inter-
viewers. However, it should be noted that low reliability
(i.e., measurement error) would attenuate existing asso-
ciations between the 4DSQ anxiety score and anxiety
disorder diagnosis. Because measurement error usually
does not correlate with anything, it is unlikely that low
reliability would be responsible for false associations. In
other words, the associations in this study, as expressed
in areas under the ROC-curve, sensitivities, specificities
and likelihood ratios, are real and provide some reassur-
ance regarding the diagnostic reliability.
This study took place in the DSM-IV era. However, in
the meantime the DSM-5 – published in May 2013 – has
decided not to classify OCD and PTSD as anxiety disor-
ders anymore [50]. Instead OCD is included in a separate
section with disorders characterized by compulsive behav-
iour, whereas PTSD is included in a section with disorders
following traumatic or stressful events. Yet, our findings
provide evidence of at least some degree of kinship be-
tween these disorders and typical anxiety disorders like
panic disorder, agoraphobia and social phobia.
Conclusions
The 4DSQ anxiety scale measures a common trait of
pathological anxiety that is characteristic of the anxiety
disorders, in particular panic disorder, agoraphobia, social
phobia, OCD and PTSD. This property enables the anxiety
scale to distinguish between patients with high risk of hav-
ing an anxiety disorder (especially panic disorder, agora-
phobia, social phobia, OCD and PTSD) and patients with
low risk. It should be noted that the 4DSQ anxiety score
is not able to distinguish between the separate anxiety
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disorder types. We propose to use ≥4 and ≥10 as cut-off
points. Scores ≥4 should serve as a prompt to consider the
possible presence of an anxiety disorder (while the prob-
ability is still relatively low), whereas scores ≥10 serve best
as a prompt to pursue a clinical diagnostic workup for
anxiety disorder immediately (as the probability is rela-
tively high).
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